One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Ähnliche Einträge

• Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
  von: Nicklas S. Klepser, et al.
  Veröffentlicht: (2025)
• The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
  von: Mario Luca Morieri, et al.
  Veröffentlicht: (2026)
• Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
  von: Sama M. Abdel‐Rahman, et al.
  Veröffentlicht: (2026)
• Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
  von: João Sérgio Neves, et al.
  Veröffentlicht: (2025)
• Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
  von: Hannah Wallace, et al.
  Veröffentlicht: (2025)